A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009.

Authors: Eleftherios P. Mamounas, Gong Tang, Shannon L. Puhalla, Sandra M. Swain, Patricia A. Ganz, Norah Lynn Henry, Reena S. Cecchini, Sonya A. Reid, Priya Rastogi, Charles E. Geyer, Julia R. White, Amy Sanders Clark, Tufia C. Haddad, Gregory A. Vidal, Norman Wolmark

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps615

Source: Full article

---

Abstract

TPS615